Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
DSGN Stock — Design Therapeutics Inc
Design Therapeutics Inc (DSGN)
Updated October 16, 2026.
DSGN is a Stock. Total return is -75.2% over the past 5.6 years, 182.6 points behind SPY at 107.4%.
Design Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs for genetic diseases, primarily those caused by nucleotide repeat expansions. The company's GeneTAC platform targets conditions including Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease. As an early-stage biotech company, it does not currently distribute income and appeals to growth-oriented investors willing to accept the risks inherent in clinical-stage drug development.
DSGN performance versus SPY
Price and return data through 2026-10-16.
Total return is -75.2% over the past 5.6 years, 182.6 points behind SPY at 107.4%. Over the past year its total return — price change plus distributions reinvested — is 67.1%. Its deepest 1-year drawdown was 39.0%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -17.5% | — |
| 3M | -18.2% | — |
| 6M | -17.6% | — |
| YTD | 9.9% | — |
| 1Y | 67.1% | — |
| 2Y CAGR | — | 35.10% |
| 3Y CAGR | — | 67.80% |
| 5Y CAGR | — | -6.30% |
| Since inception (5.6 years) | -75.2% | -22.20% |
DSGN key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 03/26/2021
- Distribution frequency
- None
- Last close
- $10.31 (as of 2026-10-16)
- Market cap
- $645,216,822
- Average volume
- 854547.0
- Beta
- 1.686
- Payout ratio
- 0.0%
- EPS
- $-1.18
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
DSGN risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.0%.
Who may consider DSGN — and who may not
It is a weaker fit for investors who need monthly cash flow (DSGN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on DSGN
Frequently asked questions
Does DSGN pay monthly?
No. DSGN does not currently distribute.
When does DSGN pay a dividend?
DSGN does not currently distribute.
How has DSGN performed?
Total return is -75.2% over the past 5.6 years, 182.6 points behind SPY at 107.4%. Over the past year its total return — price change plus distributions reinvested — is 67.1%. Its deepest 1-year drawdown was 39.0%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.